Deal terms and scope
Jiangsu Hengrui Pharmaceuticals Co Ltd and Bristol-Myers Squibb Company announced they have entered into a global strategic collaboration and license agreement that covers 13 early-stage programs focused on oncology, hematology and immunology. The companies outlined a payment schedule in which Bristol-Myers will commit up to $950 million to Hengrui under the terms announced.
Under the financial terms disclosed, Bristol-Myers will make a $600 million upfront payment at signing, followed by a $175 million payment on the first anniversary of the agreement and a further contingent anniversary payment of $175 million scheduled in 2028. The two firms also described a potential maximum economic value for the collaboration of up to $15.2 billion, subject to the achievement of milestones and other contingencies described by the parties.
Market reaction
Hengrui's shares listed in Hong Kong reacted strongly to the announcement, rising as much as 13% to HK$76.75 on Tuesday. The move in Hengrui's stock outpaced the more muted gains seen in the broader Hang Seng index the same day.
Timing and next steps
The firms indicated the deal is expected to be finalized by the third quarter of 2026. Beyond the headline payments, one element to note is that part of the $950 million total is contingent - specifically the $175 million payment slated for 2028 - which means some consideration is tied to future conditions referenced by the companies.
Context on partnerships
The announcement follows a pattern of Hengrui establishing collaborations with major pharmaceutical companies in recent years. The company has entered similar partnerships over the past three years, including deals announced in 2025 with GSK plc and Merck & Company Inc.
Implications for markets and sectors
The agreement directly affects the pharmaceutical and healthcare sectors through joint drug development exposure in oncology, hematology and immunology. The market reaction to the payment structure - including a large upfront payment and additional contingent payments - was reflected in Hengrui's share price movement on the Hong Kong exchange.
Note: The companies have provided the payment schedule and target finalization window; the eventual economic outcome will depend on the fulfillment of the agreement's conditions.